ProfileGDS5678 / 1460730_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 26% 27% 27% 29% 28% 33% 25% 28% 28% 28% 27% 28% 27% 27% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6257426
GSM967853U87-EV human glioblastoma xenograft - Control 22.6244627
GSM967854U87-EV human glioblastoma xenograft - Control 32.6277727
GSM967855U87-EV human glioblastoma xenograft - Control 42.6073629
GSM967856U87-EV human glioblastoma xenograft - Control 52.5848128
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8271933
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6154625
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6160628
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6155128
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6249328
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6168127
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6110828
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6187127
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6209127